Elanco Animal Health Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey N. Simmons
- Full Time Employees
- 9,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2500 Innovation Way Greenfield IN United States of America 46140
- IPO Date
- Sep 20, 2018
- CIK
- 0001739104
- Website
- elanco.com
- Similar Companies
- Business
- Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health that develops, manufactures, and markets innovative products and services to prevent and treat diseases in farm animals and pets. The company offers a comprehensive portfolio including parasiticides such as Credelio Quattro, Zenrelia, Advantage Family, and Seresto for pets; productivity enhancers like Experior and AdTab for cattle; vaccines, antibiotics, and feed additives for poultry and swine; and knowledge services providing data-driven insights to veterinarians, farmers, and pet owners worldwide. Elanco operates in over 100 countries with a focus on pet health and livestock sustainability segments, targeting veterinarians, farmers, pet owners, and food producers. Founded in 1954 as a division of Eli Lilly and Company and headquartered in Indianapolis, Indiana, Elanco spun off as an independent public company in 2018 and maintains manufacturing, research, and commercial operations globally. Recent strategic changes include the completed divestiture of its aqua business to Merck Animal Health for $1.3 billion in July 2024, enabling focus on core pet and farm animal growth areas; refinancing of a $2.1 billion Term Loan B facility in 2025 to extend maturities to 2032 and reduce interest costs; monetization of certain lotilaner U.S. royalties for $295 million in May 2025; and the opening of a new global headquarters in downtown Indianapolis. In third quarter 2025 results, Elanco reported organic constant currency revenue growth of 9%, driven by strong performances from Credelio Quattro (reaching $100 million in net sales within eight months), Zenrelia (global sales nearly doubling quarter-over-quarter with launches in the EU, Great Britain, and Australia), Experior (up 70% year-over-year), and AdTab (up over 25% year-over-year), while raising full-year 2025 guidance for revenue, innovation revenue, adjusted EBITDA, and adjusted EPS alongside an improved year-end net leverage ratio target of 3.7x to 3.8x.
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? GF Value Says Overvalued
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors
Elanco to Participate in Upcoming Investor Conferences
Elanco Animal Health Q1 Earnings Call Highlights
Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak
Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Reports First Quarter 2026 Results
ADUS or ELAN: Which Is the Better Value Stock Right Now?
Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock
Elanco Animal Health Incorporated $ELAN Position Decreased by Davidson Investment Advisors
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
Elanco Animal Health Incorporated $ELAN Shares Sold by Douglas Lane & Associates LLC
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*